CD47

Anyways, it's used in frontline chemotherapy for ovarian cancer.

But what Light Chain is doing, based in Switzerland, is CD47 antibodies.

Do you know what that does, Ben? We've talked about them before on the show.

Do you know the company Feast Therapeutics? or 47 therapeutics, they block the don't eat me signal on cancer cells.

You want them to remain inflammatory until the tumor is gone.

but so often we get them stuck in this immunosuppressive state.

One of the ways that we can trigger them to become more inflammatory and anti-tumor would be to let them eat the tumor cells, right? But the tumor cells tend to express CD47 and that blocks the macrophages from eating them.

But if you can block that blockade, with an antibody, you can allow the macrophages to engulf and consume the tumor cells, which will kill the tumor cells, number one.

So, like, really interesting to see that there's lots of humans who make anti-Serrp alpha antibodies.

We've never seen a human make an anti-CD47, uh, antibody.

So it's really interesting to see where sort of the gap on our intuition on, you know, is this a sampling problem which is solvable or a biological problem which is fundamentally intractable kind of land.

Um, so, you know, I, I think we were pretty right about what the positive results were going to be, and I think we have gotten better about informative negative results.

A good example of several agents in AML that failed at the phase three stage would be pevinitastat was one.

We think about magrolimab, right? So the anti-CD47.

antibody that looked promising, especially in TP53 mutated disease early on, actually had a slightly increased mortality compared to AZA plus placebo in the enhanced studies.

I think we just need to take that at its face value that this is a phase two study right now, and then hopefully we'll get a confirmatory phase three study out of it.